Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2025)
Crinetics Pharmaceuticals (CRNX) has 9 years of Enterprise Value data on record, last reported at -$101.5 million in Q4 2025.
- For Q4 2025, Enterprise Value rose 92.5% year-over-year to -$101.5 million; the TTM value through Dec 2025 reached -$101.5 million, up 92.5%, while the annual FY2025 figure was -$101.5 million, 92.5% up from the prior year.
- Enterprise Value reached -$101.5 million in Q4 2025 per CRNX's latest filing, up from -$981.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$34.6 million in Q4 2022 and bottomed at -$1.4 billion in Q4 2024.
- Average Enterprise Value over 5 years is -$519.3 million, with a median of -$351.3 million recorded in 2021.
- Peak YoY movement for Enterprise Value: plummeted 2052.27% in 2024, then skyrocketed 92.5% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$334.2 million in 2021, then soared by 89.63% to -$34.6 million in 2022, then plummeted by 1512.41% to -$558.6 million in 2023, then plummeted by 142.42% to -$1.4 billion in 2024, then skyrocketed by 92.5% to -$101.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$101.5 million in Q4 2025, -$981.4 million in Q3 2025, and -$1.2 billion in Q2 2025.